Exploring the anti-inflammatory effects of genistein in an in vitro lipopolysaccharide-induced macrophage model

Read full text
Authors: Cristina Remírez De Ganuza, Sonia López, Gracia Mendoza
Cited by: 3
References: 44

Abstract

Inflammation plays a central role in the onset and progression of numerous diseases, and macrophages are key regulators of this process through their polarization toward pro- or anti-inflammatory phenotypes. Natural bioactive compounds have emerged as promising candidates to modulate inflammatory responses. Amongst these, genistein, a soybean-derived isoflavone, was selected due to its reported anti-inflammatory and antioxidant profile across different cell types. In this study, we evaluated the effects of genistein in a lipopolysaccharide (LPS)-induced macrophage model to investigate its cellular and molecular mechanisms of action. Genistein treatment at subcytotoxic concentration preserved cell viability, did not induce apoptosis or cell cycle arrest, and reduced oxidative stress. In LPS-stimulated macrophages, treatment with 5 µg/mL genistein significantly decreased nitric oxide production and downregulated pro-inflammatory markers while upregulating an anti-inflammatory mediator, thus reverting macrophage polarization to an anti-inflammatory phenotype. Protein analyses confirmed reduced expression of iNOS and cytokines such as IL-6 and TNF-α. Furthermore, genistein restored cell morphology and inhibited NF-κB p65 nuclear translocation, indicating its capacity to counteract LPS-driven pro-inflammatory signalling. These findings support the role of genistein in modulating macrophage polarization and inflammatory responses, highlighting its therapeutic potential for the management of acute and chronic inflammation-related disorders.

Fields of Study & Subjects

Phytoestrogen effects and research Immune cells in cancer Immune Response and Inflammation

Publication details

Journal / source
Scientific Reports
Publisher
Springer Science and Business Media LLC
Volume
16
Issue
1
Publication date
2 March 2026
Language
EN